Eagle Asset Management Inc. Sells 132,053 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Eagle Asset Management Inc. cut its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 15.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 709,518 shares of the biotechnology company’s stock after selling 132,053 shares during the quarter. Eagle Asset Management Inc. owned 1.19% of Aldeyra Therapeutics worth $3,917,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE purchased a new position in shares of Aldeyra Therapeutics in the third quarter worth $30,000. SG Americas Securities LLC bought a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $38,000. Diversified Trust Co purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $41,000. Laidlaw Wealth Management LLC grew its stake in shares of Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 4,150 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 2,729 shares during the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Stock Performance

ALDX stock opened at $4.85 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The business’s 50-day moving average is $5.32 and its two-hundred day moving average is $4.62. Aldeyra Therapeutics, Inc has a fifty-two week low of $2.43 and a fifty-two week high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). On average, research analysts forecast that Aldeyra Therapeutics, Inc will post -0.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.